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Abstract 
 
Objective: To describe major events at follow up in octogenarian patients with atrial fibrillation (AF) according 
to anticoagulant treatment: direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) 
Methods: A total of 578 anticoagulated patients aged 80 years with AF were included in a prospective, 
observational, multicenter study. Basal features, embolic events (stroke and systemic embolism), severe 
bleedings, and all-cause mortality at follow up were investigated according to the anticoagulant treatment 
received.  
Results: Mean age was 84.0 + 3.4 years, 56% were women. Direct oral anticoagulants were prescribed to 123 
(21.3%) patients. Compared with 455 (78.7%) patients treated with VKAs, those treated with DOACs presented 
a lower frequency of permanent AF (52.9% vs 61.6%, P = .01), cancer history (4.9% vs 10.9%, P = .046), renal 
failure (21.1% vs 32.2%, P = .02), and left ventricular dysfunction (2.4% vs 8.0%, P = .03); and higher 
frequency of previous stroke (26.0% vs 16.6%, P = .02) and previous major bleeding (8.1% vs 3.6%, P = .03). 
There were no significant differences in Charlson, CHA2DS2VASc, nor HAS-BLED scores. At 3-year follow 
up, rates of embolic events, severe bleedings, and all-cause death (per 100 patients-year) were similar in both 
groups (DOACs vs VKAs): 0.34 vs 1.35 (P = .15), 3.45 vs 4.41 (P = .48), and 8.2 vs 11.0 (P = .18), respectively, 
without significant differences after multivariate analysis (hazard ratio [HR]: 0.25, 95% confidence interval 
[CI]: 0.03-1.93, P = .19; HR: 0.88, 95% CI: 0.44-1.76, P = .72 and HR: 0.84, 95% CI: 0.53-1.33, P = .46, 
respectively).  
Conclusion: In this “real-world” registry, the differences in major events rates in octogenarians with AF were 
not statistically significant in those treated with DOACs versus VKAs. 
Keywords: direct oral anticoagulants, vitamin K antagonists, atrial fibrillation, octogenarians, FANTASIIA 
registry. 
 
Introduction 
Direct oral anticoagulants (DOACs) have been shown to be non-inferior or superior to vitamin 
K antagonists (VKAs) regarding embolic events, severe bleeding, and all-cause death rates in 
patients with atrial fibrillation (AF) in clinical trials1 as well as in observational studies2-4. 
Subanalysis of randomized clinical trials have shown that the benefits of these therapies are 
consistent in elderly patients5-9. However, there is a paucity of “real-world” data on effectiveness 
and safety of these drugs, compared to VKAs, in octogenarian patients with AF10-15. Moreover, some 
studies have appointed the possibility of unclear safety in this particularly frail subgroup of patients 
in conditions of daily clinical practice16-17. The FANTASIIA registry (Spanish acronym for Atrial 
fibrillation: Influence of anticoagulation level and type on stroke and bleeding event incidence) is 
an observational, national, prospective, multicenter study that included patients aged 18 years or 
older with AF on anticoagulant treatment. The main objective of the study was to evaluate the 
incidence of thromboembolic and bleeding events in this population over 3 years, with focus on the 
use and type of antithrombotic agent, VKAs and DOACs, as well as anticoagulation quality (in those 
patients prescribed VKAs)18. The aim of this study was to describe basal features and major events 
at follow up in octogenarian patients with AF included in this observational “real-world” registry, 
according to the use of DOACs versus VKAs. 
Methods 
The FANTASIIA Registry 
Inclusion criteria, procedures, and main results have been previously described18. Briefly, 
patients were consecutively included at 50 outpatient clinics by 100 investigators (81% 
cardiologists, 11% primary care physicians, and 8% internists) from June 1, 2013, to October 15, 
2014. The participant centers, located throughout Spain, were selected by the steering committee, in 
order to obtain a representative sample of the whole national territory. Only physicians with clinical 
expertise and a special interest in AF were invited to participate in the study. Inclusion criteria were 
patients aged 18 years or older diagnosed of AF, who had been receiving anticoagulant therapy for 
at least 6 months before enrolment (by design, 80% VKAs and 20% DOACs, ie, dabigatran, 
rivaroxaban, or apixaban). This proportion was established to be representative of DOAC use in 
Spain at the time of the design of the study. Patients with rheumatic mitral valve disease or valvular 
prostheses were excluded. Clinical and laboratory information from the patients were collected in 
an electronic online database. The patients were managed according to the best clinical practice at 
their physician discretion. The FANTASIIA Registry adhered to the Helsinki recommendations for 
medical studies, the protocol was approved by all the local ethics committees, and patients granted 
their written informed consent. 
Design of the Study 
This is a subanalysis of the main study, focusing in octogenarian patients (those aged ≥80 years). 
For this analysis, all these patients were selected, and baseline clinical profile and major event rates 
in follow up were described, comparing patients treated with DOACs with those receiving VKAs. 
Baseline clinical profile included cardiovascular risk factors, comorbidities, heart disease history, 
AF data, physical examination, diagnostic procedures, and concomitant treatment at inclusion visit. 
Data on anticoagulation control in patients treated with VKAs in our series have been previously 
reported18,19. After the first visit, revisions appointments were scheduled after 1, 2, and 3 years, and 
major events were registered. In case of noshow to a visit, a phone contact was tried or electronic 
clinical records were consulted. Major events considered were embolic events (ischemic stroke or 
systemic embolism), severe bleeding (fatal bleeding, symptomatic bleeding in a critical area or 
organ, or causing a fall in hemoglobin level of ≥20 g/L, or leading to transfusion of ≥2 units of whole 
blood or red cells, according to the 2005 International Society of Thrombosis and Haemostasis 
criteria20), and all-cause death. 
Statistical Analysis 
Quantitative variables were reported as the mean + SD, if normally distributed, or median 
(interquartile range) otherwise. Adjustment to normal distribution was tested with the Kolmogorov–
Smirnov method. Student t test or Mann–Whitney U test (continuous variables) and χ2 test 
(qualitative variables) were used for between-group comparisons, as appropriate. Event rates were 
calculated per 100 patientsyear, and 95% confidence intervals (CIs) are provided. For multivariate 
analysis, multivariate Cox proportional hazard ratio (HR) models were constructed. In all regression 
analyses, type of anticoagulant treatment (DOACs/VKAs) was the main exposure of interest and 
forced to remain in every model. Variables initially included in the models were those univariably 
related with the main exposure of interest or the events in follow up and those with known prognostic 
value in literature. The specific variables included were age, sex, diabetes mellitus, arterial 
hypertension, chronic pulmonary obstructive disease, cancer, renal failure, hepatic dysfunction, 
heart failure, Charlson comorbidity index, coronary disease, previous stroke, previous severe 
bleeding, left ventricle dysfunction, dilated cardiomyopathy, AF type, European Heart Rhythm 
Association functional class, anticoagulant treatment (DOACs/VKAs), and anti-arrhythmics use. 
Backward stepwise regression was used to select variables in the final adjusted models. The criterion 
to remain in the model was P < .1. The results are presented as HRs with 95% CI. Goodness-of-fit 
of the models was checked by means of the Grønnesby and Borgan test21, for which P > .05 suggests 
a reasonably good adjustment. We used SPSS software version 21.0 (SPSS Inc., Chicago, Illinois) 
DSfor statistical analysis. Significance was defined as P < .05. 
Results 
Patients 
A total of 574 patients were included, with a mean age of 84.0 + 3.4 years, 55.8% were women. 
Vitamin K antagonist was the anticoagulant drug in 451 patients (78.7%) and DOACs in 123 (2.3%). 
The specific DOAC prescribed at first visit was dabigatran in 57 (46.3%) patients, apixaban in 53 
(43.1%) patients, and rivaroxaban in 13 (10.6%) patients. The baseline characteristics of the patients 
are described in Table 1. More frequent cardiovascular risk factors were hypertension, 
hypercholesterolemia, and diabetes mellitus. More significant comorbidities were chronic renal 
failure, cerebrovascular disease, and chronic pulmonary obstructive disease. Structural heart disease 
was present in nearly half of the patients. Most of them presented permanent AF, were in functional 
class I or II of the European Heart Rhythm Association (EHRA), and their embolic and bleeding 
risk was high, as assessed by CHA2 DS2-VASc and HAS-BLED scores. Diuretics, β-blockers, and 
statins were the most frequent concomitant drugs prescribed at the first visit. 
Comparison Between Basal Features of Patients Receiving DOACs Versus VKAs 
Compared to patients treated with VKAs, those who were prescribed DOACs presented a lower 
prevalence of renal failure, cancer history, dilated cardiomyopathy and permanent AF; and higher 
frequency of previous stroke and major bleeding (Table 1). Both groups presented similar age, sex, 
cardiovascular risk factors, and concomitant pharmacologic treatment. There were no significant 
differences in Charlson, CHADS2, CHA2 DS2-VASc, nor HAS-BLED scores. 
 
Events in Follow-Up 
After up to 3-year follow up (1338 patients-years of observation), 15 patients presented embolic 
events, 55 patients had severe bleedings, and 139 patients died. The differences in rates of embolic 
events, severe bleedings, cardiovascular death, all-cause death, and combined events (embolic 
events/severe bleedings or embolic events/severe bleedings/all-cause death) were not statistically 
significant between patients prescribed DOAC and those who received VKAs (Figure 1). A detailed 
description of events and crude and adjusted HRs for treatment group comparisons are shown in 
Table2.   
Predictors of Individual Events 
In multivariate analysis, only age and coronary disease independently predicted embolic events; 
renal failure, previous severe bleeding, and EHRA functional class II were independently associated 
to severe bleedings; age, diabetes, renal failure, liver dysfunction, heart failure, and EHRA 
functional class predicted cardiovascular death; and age, female sex, diabetes, chronic obstructive 
pulmonary disease, renal failure, and EHRA functional class were independently associated with 
all-cause death (Table 3). 
Discussion 
The main finding of our study was that the differences in major event rates between DOAC and 
VKA users in octogenarian patients were not statistically significant, in a prospective, multicenter, 
observational “real-world” cohort of anticoagulated patients with AF. The main clinical implication 
is that these findings support that the effectiveness and safety of DOAC are non-inferior to VKAs 
in octogenarian patients with AF in routine clinical practice.  
A high burden of cardiovascular risk factors and comorbidities was observed in our study sample, 
with a high prevalence of permanent AF and high embolic and bleeding risks. Similar findings have 
been found in the subgroup analysis of octogenarians in the pivotal clinical trials of DOACs that 
have reported baseline clinical data for these patients5,8 or in observational studies of elderly patients 
with AF10-15. However, it is remarkable that only 0.7% of patients were current smokers. Although 
a decline in the smokers proportion has been observed with age in patients with AF in a clinical 
trial,5 the rate of currents smokers in patients aged ≥75 years has been reported in the range of 3.8% 
to 8.5%. 5,12 
The decision to treat each patient with DOACs versus VKAs was made at the discretion of the 
treating physician, and some basal features of the patients, which were more frequently associated 
with the use of these drugs in our study, can give us some clues about why the selected drug was 
one or another. Hence, patients treated with DOACs presented a lower prevalence of renal failure, 
cancer history, dilated cardiomyopathy, permanent AF, and higher frequency of previous stroke and 
major bleeding. The quality of anticoagulation control in patients prescribed VKAs in our study18 
was in the range of those described in the control group of the pivotal clinical trials of DOACs5-9: 
The meantime in therapeutic range in our series was 62.2%, without significant differences among 
age groups19, versus 56.9% to 69.6% in those trials. So we can anticipate that the outcomes in the 
group treated with VKAs are in the context of a standard quality of anticoagulation.  
Rates of embolic and severe bleeding found in our study are in the range found in the subgroup 
of octogenarian patients included in the pivotal trials5,7,8. So, the embolic event rate ranged from 1.5 
to 2.8 (per 100 patients-year) with DOACs and from 1.9 to 2.9 with warfarin. In our study, embolic 
events rates were 0.3 (95% CI: 0.1-2.4) for DOACs and 1.4 (95% CI: 0.8-2.3) for VKAs. Although 
mean values are numerically lower in our series, confidence intervals are wide and include the 
figures observed in the trials. For severe bleeding events, rates observed in this subgroup of patients 
included in the pivotal trials ranged from 3.6 to 6.2 with DOAC and from 5.4 to 6.2 with warfarin, 
whereas in our study the figures were 3.5 (95% CI: 1.9-6.4) for DOACs versus 4.4 (95% CI: 3.3-
5.9) for VKAs, also consistent with those reported by the trials. 
 
Table 1. Baseline Features of the Study Sample, According to the Anticoagulant Prescribed in First Visit. 
Variable All Patients 
Direct Oral 
Anticoagulants 
Vitamin K 
Antagonists 
P 
Value 
Patients, n (%) 574 123 (21.3) 451 (78.7)  
Demographic data     
    Age  84.0 + 3.4 83.9 + 3.9 84.0 + 3.4 .82 
    Female sex (%)  55.8 61.0 54.3 .19 
Cardiovascular risk factors and concurrent disease     
Hypertension (%) 84.2 83.7 84.3 .89 
Hyperlipidemia (%)  49.0 48.0 49.2 81 
Diabetes mellitus (%) 26.8 29.3 26.2 .49 
Current smoker (%) 0.7 0 0.9 .30 
Renal failurea (%) 29.8 21.1 32.2 .02 
Chronic obstructive pulmonary          disease/sleep 
obstructive apnea syndrome 
18.3 16.3 17.6 .74 
Cancer history (%) 9.6 4.9 10.9 .046 
Liver dysfunction (%) 1.4 0.8 1.6 .54 
Aortic/peripheral artery disease (%) 5.1 6.5 4.7 .41 
Previous stroke/transient ischemic    attack (%) 18.6 26.0 16.6 .02 
Major bleeding in previous 6 months (%) 4.5 8.1 3.6 .03 
Charlson comorbidity index 1.2 + 1.1 1.1 + 1.0 1.2 + 1.1 .94 
Cardiac history     
Previous structural heart disease 48.8 44.7 49.9 .31 
Heart failure (%) 30.3 26.0 31.5 .24 
Coronary disease (%) 19.2 16.3 20.0 .36 
Previous acute coronary syndrome (%) 14.5 12.2 15.1 .42 
Coronary stents (%) 8.7 7.3 9.1 .54 
Dilated cardiomyopathy (%) 6.8 2.4 8.0 .03 
Hypertrophic cardiomyopathy (%) 1.4 0.8 1.6 .54 
Aortic valvular disease (%) 5.9 4.9 6.2 .58 
Hypertensive heart disease (%) 20.4 20.3 20.4 .99 
Atrial fibrillation–related information     
Permanent atrial fibrillation (%) 59.8 52.9 61.6 .01 
EHRA functional class III-IV (%)  13.1 8.9 14.2 .54 
CHADS2 score 2.8 + 1.1 2.9 + 1.2 2.8 + 1.1 .19 
CHA2DS2-VASc score 4.5 + 1.3 4.7 + 1.3 4.5 + 1.3 .07 
HAS-BLED score 2.4 + 0.9 2.4 +1.1 2.4 + 0.9 .63 
Examination and diagnostic procedures at initial visit     
Heart rate (bpm)  73.6 +14.6 73.2 + 15.5 73.7 + 14.4 .49 
Weight (kg) 72.6 + 11.5 71.6 + 10.3 72.9 + 11.8 .42 
Height (cm) 161.5 + 8.5 161.4 + 8.8 161.5 + 8.4 .67 
Body mass index (kg/m) 27.9 + 4.1 27.5 + 3.7 27.9 + 4.2 .22 
Creatinine clearance (mL/min) 55.6 + 16.8 58.7 + 18.1 54.8 + 16.3 .05 
Pharmacologic treatment at inclusion visit     
Diuretics (%)  63.9 56.9 65.9 .07 
Aldosterone antagonists (%) 13.6 9.8 14.6 .16 
Angiotensin-converting enzyme inhibitors (%) 31.5 29.3 32.2 .54 
Angiotensin receptor blockers (%)  40.2 40.7 40.1 .92 
Statins (%)  52.1 54.5 51.4 .55 
Antiplatelet agents (%) 11.0 14.6 10.0 .14 
β-blockers (%) 54.0 50.4 55.0 .37 
Digoxin (%)  21.3 22.8 20.8 .64 
Calcium antagonists (%) 23.5 29.3 22.0 .22 
Anti-arrhythmics use (%)  14.5 15.5 14.2 .73 
Abbreviation: EHRA, European Heart Rhythm Association. 
aRenal failure was considered if glomerular filtration rate was lower than 60 mL/min.   
 
In the comparison between DOACs and VKAs, subgroup analyses of pivotal randomized clinical 
trials have shown, for patients aged ≥75 years, similar results to the rest of the population included5-
9, and outcomes for patients 80 years or older have been reported by most of them5,7,8. In general, 
these older subgroup of patients presented higher rates of embolic and bleeding events, and all-cause 
mortality than younger patients. Efficacy was similar for dabigatran rivaroxaban, and edoxaban 
versus warfarin 5,6,8 and better for apixaban7. Safety regarding major bleeding was similar for 
rivaroxaban6 and low dose dabigatran5 versus warfarin, higher with apixaban7 and edoxaban8, and 
lower for the high dose of dabigatran5, supporting the selection of dabigatran 110 mg twice daily for 
octogenarian patients. Due to the reduced number of patients receiving each DOAC, we have not 
been able to do an individualized analysis. However, our overall results appear consistent with 
clinical trial data regarding comparative effectiveness and safety of DOACs versus VKAs9. 
 
 
Figure 1. Kaplan–Meier curves for embolic events (A), severe bleedings (B), all-cause mortality (C) and the combined end 
point of embolic events/severe bleedings/all-cause death (D), according to anticoagulant treatment prescribed at first visit. 
DOAC indicates direct oral anticoagulant; VKA, vitamin K antagonists 
There is some evidence of observational studies on the efficacy and safety of DOACs in elderly 
patients10-15. The designs have been retrospective analysis of administrative databases10,15or 
monocentric prospective11,12 or retrospective14 studies, and recently, a prospective, nationwide, 
multicentric Italian study addressing the specific subgroup of patients aged 80 years or older has 
been published13. However, the results have generally been consistent with those found in our study: 
Different clinical profile has been reported for elderly patients treated with DOACs versus 
VKAs10,12-15, and similar stroke or bleeding risk with both treatments10,12,13, even for those aged 90 
years or older10, but with benefits for intracranial hemorrhage incidence10,15. Rates of embolic events 
of 0.9% (95% CI: 0.8-0.9) and major bleeding events of 4.4% (95% CI: 1.7-7.2), similar to those 
found in our study, have been reported for patients aged 82 ± 6 years with AF treated with DOACs 
in a monocentric observational prospective study11. The Italian multicentric study also found similar 
figures (1.5% vs 1.3% for embolic events and 3.4% vs 3.7% for severe bleedings in patients 
receiving DOACs vs VKAs, respectively) in a population of 756 propensity-matched patients with 
a mean age of 85 ± 3 years, although a benefit in overall survival was observed in this work13. 
Perhaps the larger size of the sample made it possible to detect this difference in mortality that we 
did not appreciate in our study. Finally, 2 recently published observational retrospective studies 14,15 
have reported benefits in overall mortality of DOACs versus VKAs in octogenarian patients, with 
one of them14 describing a lower incidence of thromboembolic events and major bleeding, and the 
other15, of intracranial hemorrhage and cardiovascular death. Curiously, both of them have been 
performed in Asian countries, where control of anticoagulation with VKAs has been reported to be 
suboptimal22, and this fact could be another possible explanation of the benefit found. 
We found that only age and coronary artery disease were associated with embolic events in this 
sample of anticoagulated patients with AF aged ≥80 years. Previous observational and post hoc 
analysis of clinical trials including octogenarians13 and a wider spectrum of age23,24 have found those 
variables to be associated with this outcome, as well as other factors, as chronic kidney disease13, 
that we have not been able to confirm, possibly due to lack of statistical power. Renal failure, 
previous severe bleeding, and EHRA functional class II were independently associated with severe 
bleeding in our study. The first 2 factors have been previously reported as predictors of severe 
bleeding in anticoagulated patients in the literature24,25. As far as we know, EHRA functional class 
II had not been described as a predictor of bleeding. Finally, age, female sex, diabetes, chronic 
obstructive pulmonary disease, renal failure, and advanced EHRA functional class were associated 
with all-cause death, and most of these factors, as well as heart failure and liver dysfunction, with 
cardiovascular death. Again, although most risk factors had been previously described in the 
analyses of octogenarians13 and broader age populations of anticoagulated patients with AF26,27, this 
is the first report of advanced EHRA functional class as a strong predictor of allcause mortality in 
this specific population. Although it is not strange to think that worse symptomatic status can have 
an adverse prognostic impact, this variable had not been considered in the multivariate analysis of 
previous studies13,23,27. 
Our study has some strengths. First, the multicenter, nationwide nature of this registry can be 
representative of the reality of the studied subgroup of patients in our country. Moreover, this is a 
prospective study with investigators-adjudicated end points, hence overcoming the uncertainties of 
retrospective administrative databases analysis. On the other hand, main limitations are the limited 
sample size, which makes it impossible to exclude a significant, albeit small, difference between 
both treatment groups, and which has precluded an individual drug analysis of results; the absence 
of patients treated with edoxaban that was not commercially available in Spain during the study 
period; the selection of physicians with clinical expertise and a special interest in AF to participate 
in the study, which makes it uncertain if the results might be different had a more general sample of 
medical doctors been included; the fact that only outpatients were selected, so our results should 
only be extrapolated very cautiously to frail patients during hospital admissions or cared in hospice 
facilities; and finally, we must acknowledge that the intergroup differences require consideration. 
Although we used multivariate analysis to attempt to adjust for these differences, propensity score 
matching would have been an alternative approach; however, our sample size limits the likely 
efficacy of this method. Future studies should examine registries with larger sample sizes, including 
this statistical approach. 
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Table 3. Variables Included in the Final Multivariate Models for Each Event of Interest, Besides Anticoagulant Treatment. 
 
Events and Associated Variables  Hazard Ratio  95% Confidence Interval  P Value  
Embolic events    
  Age 1.17 1.03-1.32 .02 
  Coronary disease 3.09 1.09-8.76 .03 
Severe bleedings    
  Renal failure  2.4 1.4-4.11 .001 
  Previous severe bleeding  5.11 2.28-11.46 <.001 
  EHRA functional class IIa 2.91 1.30-6.52 .009 
  EHRA functional class IIIa 1.92 0.6-6.14 .27 
  EHRA functional class IVa 0.00   
Embolic events or severe bleedings    
  Renal failure 2.19 1.34-3.56 .002 
  Previous severe bleeding 4.78 2.15-10.66 <.001 
  EHRA functional class IIa 2.40 1.21-4.77 .01 
  EHRA functional class IIIa 1.68 0.60-4.66 .32 
  EHRA functional class IVa 0.00   
  Antiarrhythmic treatment 0.38 0.14-1.05 .06 
Cardiovascular death    
  Age 1.10 1.03-1.18 .007 
  Diabetes mellitus 2.43 1.43-4.14 .001 
  Renal failure 2.32 1.37-3.94 .002 
  Liver dysfunction .36 1.03-18.45 .046 
  Heart failure 2.06 1.18-3.6 .01 
  EHRA functional class IIa 2.31 0.96-5.54 .06 
  EHRA functional class IIIa 4.78 1.82-12.58 .002 
  EHRA functional class IVa 0.00   
All-cause death    
  Age 1.09 1.04-1.14 <.001 
  Female sex  0.67 0.47-0.95 .03 
  Hypertension  1.65 0.94-2.90 .08 
  Diabetes mellitus  1.59 1.10-2.30 .01 
  Chronic obstructive pulmonary disease 1.54 1.03-2.31 .04 
  Renal failure 1.69 1.18-2.40 .004 
  Previous severe bleeding 1.87 0.93-3.76 .08 
  Persistent AF2 1.09 0.54-2.19 .81 
  Long-standing persistent AFb 2.13 0.95-4.78 .07 
  Permanent AF2 1.62 0.99-2.65 .06 
  EHRA functional class IIa  2.19 1.31-3.67 .003 
  EHRA functional class IIIa 3.91 2.12-7.19 <.001 
  EHRA functional class IVa 18.86 4.13-86.18 <.001 
Embolic events, severe bleedings, or all-cause death    
  Age 1.08 1.03-1.12 .001 
  Female sex 0.69 0.51-0.94 .02 
  Renal failure   1.83 1.34-2.51 <.001 
  Previous stroke/transient ischemic attack 0.62 0.40-0.96 .03 
  Charlson index   1.27 1.10-1.47 .001 
  Previous severe bleeding 2.35 1.32-4.19 .004 
  EHRA functional class IIa  1.88 1.22-2.87 .004 
  EHRA functional class IIIa 3.04 1.79-5.16 <.001 
  EHRA functional class IVa 11.67 2.66-51.14 .001 
 
Abbreviations: AF, atrial fibrillation; EHRA, European Heart Rhythm Association.  
aConsidering EHRA functional class I as reference. 
bConsidering paroxysmal AF as reference. 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion  
In this nationwide, “real-world” registry of octogenarian patients with AF, different basal 
features were found between patients treated with DOACs and those who received VKAs. The 
differences in major events rates between patients treated with DOACs and VKAs did not reach 
statistical significance. These results are reassuring in the safety and effectiveness of these drugs in 
this special population in a daily clinical practice setting. 
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